Vantage logo

Mustang and the bubble boy bubble

The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.

Vantage logo

Should gene therapy patients be asked to pay?

The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…

Vantage logo

Fibrocell gets a reality check

Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.